Sign In
Buy BBIO
$80.09
-2.05 (-2.50%)
At Close: Jul 31, 2026
BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress
01:29pm, Monday, 02'nd Mar 2020
-Achieved multiple clinical and pre-clinical milestones across BridgeBio’s pipeline -Delivered pipeline expansion with addition of five new drug development and discovery.
Griekenland en Italië zijn nu veilige havens
12:00am, Monday, 02'nd Mar 2020
Forex Analyses door Cor Wijtvliet (Cor Wijtvliet) over: . Lees Cor Wijtvliet (Cor Wijtvliet)'s Forex Analyses op Investing.com.
Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO)
12:42pm, Saturday, 29'th Feb 2020
In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on BridgeBio Pharma (BBIO – Research
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and BridgeBio Pharma (BBIO)
09:12am, Wednesday, 26'th Feb 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fate Therapeutics (FATE) and BridgeBio Pharma (BBIO) with
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (NASDAQ: FATE) and BridgeBio Pharma (NASDAQ: BBIO)
09:12am, Wednesday, 26'th Feb 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fate Therapeutics
BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board of Directors
12:30pm, Monday, 24'th Feb 2020
BridgeBio Pharma, Inc. (BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced it has appointed Ronald J. Daniels, president of Johns Hopkins University, to its board
Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO)
03:12pm, Saturday, 22'nd Feb 2020
In a report released today,
Salim Syed
from Mizuho Securities maintained a
Buy
rating on BridgeBio Pharma (
BBIO
–
Research Report
), with a price target of
$51.00
. The company’s shares closed la
BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences
12:25am, Saturday, 22'nd Feb 2020
PALO ALTO, Calif., Feb. 21, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), together with affiliate company Eidos Therapeutics (Nasdaq: EIDX) announced today that they are.
BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences
12:25am, Saturday, 22'nd Feb 2020
PALO ALTO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), together with affiliate company Eidos Therapeutics (Nasdaq:...
Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs
03:35pm, Wednesday, 19'th Feb 2020
Company’s shares up 70% just days after public offering Continue reading...
Stifel likes Alector and Denali in premarket analyst action
12:06pm, Wednesday, 19'th Feb 2020
Alector (NASDAQ:ALEC) initiated with Buy rating and $44 (52% upside) price target at Stifel.Aridis Pharmaceuticals (NASDAQ:ARDS) initiated with Buy rating and $18 (193% upside) price target at Roth Ca
Andreas Halvorsen Trims Adaptive Biotechnologies Stake
04:27pm, Monday, 03'rd Feb 2020
The immune-driven biotech company went public last June Continue reading...
Hedge Fund Favorites vs. Kennametal Inc. (KMT) In 2019
03:36pm, Monday, 13'th Jan 2020
We are still in an overall bull market and many stocks that smart money investors were piling into surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gain
BridgeBio Pharma, Inc. (BBIO) today disclosed four additional assets in its pipeline, expanding the number of disclosed programs to over 20 potential medicines. BridgeBio’s world-class team of expe
BridgeBio Pharma, Inc. (BBIO) today announced a collaboration agreement with Catalent to establish dedicated gene therapy development and manufacturing capacity at Catalent’s Paragon Gene Therapy cl
